ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Humulin (human insulin) by Quarter
Humulin (human insulin) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly Humulin (human insulin): $280M in Q4 2024, up 49.0% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2024 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K FY2024 (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up humulin (human insulin)
Cite this data
StockData. (2026). Eli Lilly Humulin (human insulin) ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-humulin-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.